PTK2 and mesothelioma: More recently, preclinical as well as clinical data have suggested that in mesothelioma patients, low expression of merlin, a cytoskeleton protein encoded by the tumor suppressor gene NF2, may be correlated with sensitivity to FAK inhibitors, however, even in this selected “merlin-low” patient subgroup stable disease was the best treatment outcome4,5.